Aytu Biopharma, Inc.
AYTU
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Aytu BioPharma, Inc. is a pharmaceutical company whose product portfolio includes Adzenys XR-ODT, a Schedule II controlled substance amphetamine product indicated for ADHD. The U.S. Food and Drug Administration requires that all amphetamine products intended for human use be tested for safety and efficacy in animal models as part of the regulatory approval process. Aytu BioPharma’s development and marketing of this product is contingent upon this animal testing. The company’s 10-K filing acknowledges that its products are subject to regulations governing “preclinical testing and clinical trials,” which standardly involve animal studies. There is no public evidence that Aytu BioPharma has adopted a corporate policy to eliminate or replace animal testing in its product development pipeline.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.